Alteogen Inc. has filed an IND to begin clinical trials with its biosimilar version of Eylea (aflibercept) in South Korea, moving forward with its plan to become a global first mover for the biosimilar product both at home and abroad.
The planned randomized, double-blind Phase I trial will evaluate the safety, efficacy and pharmacokinetics of ALT-L9, its biosimilar of
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?